FDA Reaches Alignment on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington Disease

The FDA has agreed that a scale used in ongoing phase 1/2 clinical trials could potentially serve as an intermediate clinical end point for accelerated approval pathway for uniQure’s investigational gene therapy AMT-130.:

Source: Neurology Read More